Price
Financials
Standalone, Rs crore| Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 113 | 95 | 88 | 96 | 91 | 95 | 89 | 88 | 80 | 84 | 82 | 95 |
| Expenses | 99 | 84 | 94 | 92 | 86 | 94 | 82 | 84 | 78 | 80 | 70 | 84 |
| Operating Profit | 14 | 11 | -6 | 4 | 5 | 0 | 7 | 4 | 2 | 4 | 12 | 11 |
| OPM % | 12% | 12% | -7% | 4.4% | 5.0% | 0.5% | 7% | 4.4% | 2.6% | 4.5% | 15% | 12% |
| Other Income | 3 | 1 | 0 | 1 | 1 | 1 | 2 | 1 | -765 | -3,008 | 2 | 1 |
| Interest | 83 | 80 | 95 | 97 | 98 | 103 | 112 | 111 | 114 | 237 | 148 | -102 |
| Depreciation | 66 | 66 | 66 | 66 | 66 | 67 | 61 | 61 | 61 | 61 | 61 | 61 |
| Profit before tax | -132 | -134 | -167 | -158 | -158 | -167 | -165 | -168 | -938 | -3,303 | -195 | 53 |
| Tax % | -35% | -35% | -35% | -35% | -29% | -35% | 0% | 0% | -40% | -30% | -30% | 30% |
| Net Profit | -86 | -88 | -110 | -103 | -112 | -110 | -165 | -168 | -563 | -2,309 | -136 | 37 |
| EPS in Rs | -3.17 | -3.22 | -4.02 | -3.79 | -4.12 | -4.02 | -6.05 | -6.17 | -20.69 | -84.84 | -5.00 | 1.36 |
| Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Mar 2016 15m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,617 | 1,662 | 835 | 718 | 667 | 524 | 368 | 352 | 350 | 346 | 343 | 408 |
| Expenses | 920 | 1,121 | 687 | 623 | 587 | 460 | 356 | 338 | 306 | 536 | 305 | 461 |
| Operating Profit | 697 | 541 | 148 | 95 | 80 | 64 | 13 | 14 | 44 | -190 | 38 | -53 |
| OPM % | 43% | 33% | 18% | 13% | 12% | 12% | 3.4% | 4.0% | 13% | -55% | 11% | -13% |
| Other Income | -52 | 9 | 6 | 4 | 4 | 8 | 4 | -767 | -3,008 | 4 | 75 | 8 |
| Interest | 230 | 270 | 412 | 438 | 470 | 415 | 370 | 440 | 259 | 0 | 0 | 2 |
| Depreciation | 198 | 252 | 259 | 254 | 277 | 345 | 264 | 246 | 246 | 246 | 245 | 243 |
| Profit before tax | 217 | 28 | -518 | -593 | -662 | -688 | -617 | -1,438 | -3,468 | -432 | -133 | -290 |
| Tax % | 33% | 31% | -32% | -32% | -31% | -34% | -33% | -30% | -4% | 0% | 536% | 2% |
| Net Profit | 145 | 19 | -350 | -401 | -458 | -450 | -412 | -1,005 | -3,330 | -432 | -844 | -295 |
| EPS in Rs | 5.42 | 0.71 | -13.06 | -14.96 | -16.82 | -16.55 | -15.15 | -36.94 | -122.36 | -15.89 | -31.00 | -10.85 |
| Dividend Payout % | 9% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | -13% | 2% | 5% | 19% | ||
| Compounded Profit Growth | % | 5% | 3% | 65% | ||
| Stock Price CAGR | -16% | % | % | % | ||
| Return on Equity | % | % | % | % |
| Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 |
| Reserves | 2,444 | 2,464 | 1,844 | 1,443 | 1,010 | 1,637 | 1,249 | 249 | -4,190 | -4,623 | -5,466 | -5,760 |
| Borrowings | 3,744 | 4,255 | 4,990 | 5,868 | 6,105 | 6,568 | 6,949 | 7,493 | 3,223 | 7,969 | 7,900 | 7,984 |
| Other Liabilities | 433 | 389 | 223 | 61 | 70 | 129 | 130 | 109 | 4,642 | 123 | 130 | 181 |
| Total Liabilities | 6,648 | 7,134 | 7,084 | 7,399 | 7,213 | 8,360 | 8,355 | 7,877 | 3,703 | 3,495 | 2,591 | 2,432 |
| Fixed Assets | 2,845 | 2,942 | 3,633 | 3,433 | 3,274 | 2,965 | 2,726 | 2,488 | 2,244 | 1,998 | 1,760 | 1,520 |
| CWIP | 1,263 | 1,646 | 1,552 | 2,110 | 2,270 | 2,450 | 2,442 | 2,503 | 0 | 0 | 0 | 0 |
| Investments | 364 | 365 | 377 | 377 | 169 | 1,552 | 1,582 | 1,586 | 2 | 2 | 3 | 3 |
| Other Assets | 2,176 | 2,182 | 1,522 | 1,479 | 1,500 | 1,393 | 1,604 | 1,299 | 1,457 | 1,495 | 829 | 909 |
| Total Assets | 6,648 | 7,134 | 7,084 | 7,399 | 7,213 | 8,360 | 8,355 | 7,877 | 3,703 | 3,495 | 2,591 | 2,432 |
| Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 348 | 370 | 811 | 172 | 256 | 67 | 1 | -33 | 58 | 20 | 32 | 87 |
| Cash from Investing Activity | -994 | -733 | -812 | -315 | 17 | -84 | -49 | -9 | -1 | 1 | -4 | 1 |
| Cash from Financing Activity | 675 | 227 | -4 | 143 | -273 | 16 | 49 | 38 | -2 | 0 | 0 | 0 |
| Net Cash Flow | 29 | -136 | -4 | -0 | 0 | -1 | 0 | -4 | 55 | 21 | 28 | 88 |
| Free Cash Flow | -557 | -362 | 11 | -143 | 65 | -17 | -49 | -42 | 57 | 20 | 25 | 85 |
| CFO/OP | 54% | 76% | 550% | 183% | 320% | 114% | 5% | -233% | 132% | -11% | 84% | -164% |
| Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 153 | 159 | 152 | 171 | 99 | 29 | 43 | 53 | 42 | 45 | 52 | 32 |
| Inventory Days | 313 | 419 | 547 | 566 | 498 | 739 | 939 | 88 | 91 | 101 | 134 | 117 |
| Days Payable | 23 | 18 | 17 | 14 | 19 | 23 | 51 | 30 | 35 | 25 | 36 | 28 |
| Cash Conversion Cycle | 442 | 559 | 682 | 722 | 577 | 745 | 931 | 112 | 98 | 121 | 149 | 121 |
| Working Capital Days | 427 | -145 | -1,060 | -1,812 | -965 | -1,042 | -2,008 | -5,340 | -6,017 | -6,299 | -6,272 | -5,392 |
| ROCE % | 9% | 6% | -2% | -2% | -3% | -4% | -3% | -3% | -6% | -36% | -5% | -12% |
| Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 24.64% | 24.64% | 24.64% | 24.64% | 24.64% | 24.64% | 24.64% | 24.64% | 24.64% | 24.64% | 24.64% | 24.64% |
| FIIs | 21.93% | 21.93% | 21.93% | 21.93% | 21.93% | 21.93% | 21.93% | 21.93% | 21.93% | 21.93% | 21.93% | 21.92% |
| Public | 53.43% | 53.43% | 53.43% | 53.43% | 53.43% | 53.43% | 53.43% | 53.43% | 53.43% | 53.43% | 53.43% | 53.43% |
| No. of Shareholders | 35,165 | 35,233 | 35,247 | 35,301 | 35,290 | 35,271 | 35,257 | 35,238 | 35,233 | 35,216 | 35,203 | 35,184 |
Fundamentals
Market Cap₹ 19.0 Cr.
Current Price₹ 0.70
Book Value₹ -211
ROCE-12.2 %
ROE%
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)19%
Compounded Profit Growth (TTM)65%
Standalone figures.
Valuation
Market capRs 19 Cr
Enterprise valueRs 7,805 Cr
Price to book-0.00x
Price to sales0.06x
EV / sales22.90x
Price to cash flow0.22x
Earnings yield-15596.64%
P/B, 3-year average-0.00x
P/B, 5-year average0.04x
Profitability
Operating margin (excl. other income)-13.01%
Operating margin (incl. other income)-11.03%
EBITDA margin-1097.49%
Pre-tax margin-1285.86%
Net profit margin-871.78%
Net margin, latest quarter38.94%
ROE5.29%
ROCE-12.22%
ROA-11.75%
ROE, 3-year average10.66%
ROCE, 3-year average-17.43%
ROA, 3-year average-17.16%
ROE, 5-year average14.75%
ROCE, 5-year average-31.75%
ROA, 5-year average-24.28%
ROIC (approx.)-197.73%
Tax rate-1.83%
Other income / net worth-0.14%
Growth
Sales growth (latest year)19.11%
Sales CAGR, 3 years5.30%
Sales CAGR, 5 years2.07%
Sales growth QoQ15.85%
Sales growth YoY (latest quarter)8.38%
Per share
EPS (TTM)Rs -109.18
EPS (latest year)Rs -10.85
EPS (latest quarter)Rs 1.36
EPS, 3-year averageRs -19.24
EPS, 5-year averageRs -23.67
Book value per shareRs -210.62
Sales per shareRs 12.52
Cash flow per shareRs 3.21
Free cash flow per shareRs 3.12
Efficiency
Asset turnover0.17x
Fixed asset turnover0.27x
Inventory turnover3.21x
Inventory days114 days
Debtor days32 days
Debtors turnover11.37x
Creditor days28 days
Cash conversion cycle121 days
Working capital days-5392 days
Leverage
Total debtRs 7,984 Cr
Cash and bankRs 198 Cr
Net debtRs 7,786 Cr
Debt to equity-1.39x
Interest coverage-10.06x
Owners' fund to total sources-235.68%
Debt to assets328.25%
Cash flow
Cash from Operating Activity (latest year)Rs 87 Cr
Cash from Investing Activity (latest year)Rs 1 Cr
Net Cash Flow (latest year)Rs 88 Cr
Free cash flow (latest year)Rs 85 Cr
FCFE (approx.: FCF + change in debt)Rs 169 Cr
Sales to cash flow4.68x
Statement figures
Net sales (TTM)Rs 341 Cr
Net sales (latest year)Rs 408 Cr
Sales (latest quarter)Rs 95 Cr
Operating profit excl. other income (latest year)Rs -53 Cr
Operating profit (latest quarter)Rs 11 Cr
Other income (TTM)Rs -3,770 Cr
EBITDA (TTM)Rs -3,741 Cr
PBDT (TTM)Rs -4,137 Cr
Profit before tax (TTM)Rs -4,383 Cr
Tax (latest year)Rs 5 Cr
Net profit (TTM)Rs -2,971 Cr
Net profit (latest year)Rs -295 Cr
Net profit (latest quarter)Rs 37 Cr
Depreciation (TTM)Rs 246 Cr
Depreciation (latest quarter)Rs 61 Cr
Interest (TTM)Rs 396 Cr
Cost of goods sold (latest year)Rs 297 Cr
Total expenditure (latest year)Rs 461 Cr
Total income (latest year)Rs 416 Cr
Share capitalRs 27 Cr
ReservesRs -5,760 Cr
Shareholders' fundsRs -5,733 Cr
Total assetsRs 2,432 Cr
Net blockRs 1,520 Cr
InvestmentsRs 3 Cr
ReceivablesRs 36 Cr
InventoryRs 92 Cr
Other liabilitiesRs 181 Cr
Shares outstanding (crore)27.22
Ownership
Promoter holding24.64% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 0.07 is at the 27th percentile (median 0.07).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | STERLINBIO | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +0.0% | -2.8% | +2.8 pts |
| 1 month | -51.7% | -6.8% | -44.9 pts |
| 3 months | -79.7% | -7.6% | -72.1 pts |
| 6 months | -78.8% | +0.4% | -79.2 pts |
| 1 year | -83.1% | -9.9% | -73.2 pts |
| 2 years | -81.3% | -13.6% | -67.8 pts |
| 3 years | -86.0% | +14.2% | -100.2 pts |
| 5 years | -87.0% | +27.9% | -114.9 pts |
Red flags
F-score 5 of 8| serious | Negative equity Shareholders' equity is negative |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Dec 2018Sales ₹95 Cr +8.0% vs Dec 2017.
Net profit ₹37 Cr +122.0%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2017-09-21 | Annual General Meeting | |
| 2016-09-21 | Annual General Meeting | |
| 2015-06-19 | Annual General Meeting | |
| 2014-06-20 | Annual General Meeting | |
| 2013-06-21 | Annual General Meeting | |
| 2012-06-22 | Annual General Meeting | |
| 2011-06-21 | Annual General Meeting And Dividend Re.0.50 Per Share | |
| 2010-06-21 | Dividend-Re.0.50 Per Share | |
| 2009-06-19 | Agm/Div-Re.0.50 Per Share | |
| 2008-05-22 | Agm/Dividend - 50% | |
| 2007-05-03 | Agm/Div-Re.0.50 Per Share | |
| 2006-06-15 | Dividend-50% |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Sterling Biotech Ltd?
Sterling Biotech Ltd (STERLINBIO) has a market capitalisation of Rs 19.0 Cr. at the 2018-11-05 close.
What were Sterling Biotech Ltd's latest quarterly results?
In the Dec 2018 quarter, Sterling Biotech Ltd sales was Rs 95 Cr (+8.0% vs Dec 2017) and net profit was Rs 37 Cr.